They've tested it in solid tumors, which included breast and ovarian, and saw efficacy...but I've never seen the individual breakdown in those trials. The company is still talking about possibly testing it in ovarian. They should run a small Ph2 trial in ovarian before committing to a Phase 3.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.